Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Revenue projections:

Revenue projections for CRL
Revenue projections for CRL

The projected decline in CRL's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.348000
forwardPE 22.075132
debtToEquity 105.047000
earningsGrowth 0.000000
revenueGrowth -0.027000
grossMargins 0.345850
operatingMargins 0.151130
trailingEps -4.810000
forwardEps 12.686220

CRL's current ratio, being 1.348, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, CRL is well-equipped to meet its immediate financial obligations without any difficulties.
With CRL's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
CRL's high debt-to-equity ratio reveals that the company is heavily reliant on debt for financing. This high level of leverage increases the risk of financial strain if profits decline or interest rates rise.
CRL's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.

Price projections:

Price projections for CRL
Price projections for CRL

Over time, price projections for Charles River Laboratories International, Inc. have been gradually revised upward, reflecting increasing optimism about the company's future performance. This trend suggests analysts are growing more confident in Charles River Laboratories International, Inc.'s ability to deliver strong results and achieve higher market value.

Insider Transactions:

Insider Transactions for CRL
Insider Transactions for CRL


7 CRL shares were sold in recent transactions, with market price at 213.91428702218192.CRL stock was bought in 1 transactions, while the market price was at 175.69000244140625.There is no noticeable trend in insider transactions, making it difficult to assess whether the company is headed in a positive or negative direction.

Recommendation changes over time:

Recommendations trend for CRL
Recommendations trend for CRL


A recent buy bias from analysts toward CRL indicates strong confidence in the stock's future performance. This could encourage investors to park their money in CRL, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.